EUVIMEDEUVIMED entdecken
Übersichtsarbeit

IL ‐6 in the spotlight: From cardiovascular pathophysiology to therapy

Alberto Preda, Amedeo Tirandi, Giulio Leo, Davide Di Vece, Gemma Vilahur iD, Aldo Bonaventura, Elena Osto iD, Stefano Ministrini iD, Simon Kraler iD, Petra Kleinbogard, Giovanni Camici iD, Federico Carbone iD und 2 weitere

European Journal of Clinical Investigation · 2026-01 · 56 (1)

DOI: 10.1111/eci.70161 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 03.12.2025. Verfasst von Alberto Preda und 13 weiteren Autor:innen. Beteiligte Einrichtung: De Gasperis Cardio Center, Electrophysiology Unit, Niguarda Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Interleukin-6, Cardiovascular Diseases. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 159 Literaturangaben. Gefördert von: European Cooperation in Science and Technology, Deutsche Forschungsgemeinschaft, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Interleukin‐6 (IL‐6), a pro‐inflammatory cytokine and anti‐inflammatory myokine, is involved in immune regulation and metabolic control. Persistent IL‐6 activation, particularly via trans‐signalling, is implicated in endothelial dysfunction, atherosclerosis, myocardial fibrosis, and adverse remodelling.

Methods

This review summarizes experimental, genetic, and clinical evidence on the role of IL‐6 in cardiovascular disease (CVD), focusing on the molecular pathways, prognostic value, and its potential as a therapeutic target. Experimental and genome‐wide association studies, as well as clinical trials—including IL‐6–targeted interventions—are comprehensively reviewed.

Results

While acute activation of IL‐6/STAT signalling, that is, before or during myocardial infarction, is protective, chronic activation leads to maladaptive changes in the myocardium. Mechanistically, IL‐6 promotes vascular inflammation, monocyte recruitment, coagulation, and fibrosis. Mendelian randomization implies a causal role of IL‐6 signalling in coronary artery disease, stroke, and atrial fibrillation. Simultaneously, elevated IL‐6 levels predict adverse outcomes in acute coronary syndromes and heart failure. Pharmacological IL‐6 inhibition reduces systemic inflammation, with pilot data implying acceptable safety profiles. Large phase III outcome trials are ongoing, shedding light on the impact of IL‐6 blockade in high‐risk populations, such as those with chronic kidney disease and heart failure with preserved or mildly reduced ejection fraction.

Conclusions

IL‐6 plays a dual role‐protective versus pathogenic and acute versus chronic. Chronic IL‐6 links inflammation and metabolic dysregulation to structural cardiovascular damage. Chronic IL‐6 activation requires therapeutic approaches tailored to disease context, timing and signalling mode. The results of ongoing trials will clarify whether IL‐6–targeted interventions can be integrated into cardiovascular prevention and management strategies, complementing established therapies and addressing residual inflammatory risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-6Cardiovascular DiseasesHumansSignal TransductionInflammationGenome-Wide Association StudyHeart FailureAcute Coronary Syndrome

Stichwörter der Autor:innen

IL‐6cardiovascular diseasechronic kidney diseaseheart failureinflammationmonoclonal antibodies

Substanzen

Interleukin-6

Autor:innen und Institutionen

  • De Gasperis Cardio Center, Electrophysiology Unit, Niguarda Hospital, Milan, Italy.
  • Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
  • Department of Internal Medicine, University of Genoa, Genoa, Italy.
  • Cardiology Department, University of Modena and Reggio Emilia, Modena, Italy.
  • Internal Medicine B, University Medicine Greifswald, Greifswald, Germany.
  • Research Institute, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain.

ORCID-Profile: Gemma Vilahur, Elena Osto, Stefano Ministrini, Simon Kraler, Giovanni Camici, Federico Carbone, Fabrizio Montecucco, Luca Liberale

Förderung

  • European Cooperation in Science and Technology
  • Deutsche Forschungsgemeinschaft
  • Ministero della Salute

Zitieren

APA

Preda, A., Tirandi, A., Leo, G., Di Vece, D., Vilahur, G., Bonaventura, A., Osto, E., Ministrini, S., Kraler, S., Kleinbogard, P., Camici, G., Carbone, F., Montecucco, F., & Liberale, L. (2026). IL ‐6 in the spotlight: From cardiovascular pathophysiology to therapy. European Journal of Clinical Investigation, 56(1). https://doi.org/10.1111/eci.70161

Vancouver

Preda A, Tirandi A, Leo G, Di Vece D, Vilahur G, Bonaventura A, et al. IL ‐6 in the spotlight: From cardiovascular pathophysiology to therapy. European Journal of Clinical Investigation. 2026;56(1). doi:10.1111/eci.70161

BibTeX
@article{Preda2026,
  author = {Preda, Alberto and Tirandi, Amedeo and Leo, Giulio and Di Vece, Davide and Vilahur, Gemma and Bonaventura, Aldo and Osto, Elena and Ministrini, Stefano and Kraler, Simon and Kleinbogard, Petra and Camici, Giovanni and Carbone, Federico and Montecucco, Fabrizio and Liberale, Luca},
  title = {IL ‐6 in the spotlight: From cardiovascular pathophysiology to therapy},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  volume = {56},
  number = {1},
  doi = {10.1111/eci.70161}
}
Kostenlos starten →